Latest News - Johnson & Johnson
Top Corporates Hub
Johnson & Johnson
JNJ Q1 MedTech Preview: Key Drivers and China Headwinds to Watch
02.04.2026 14:03
JNJ's MedTech unit rides cardiovascular strength and new product adoption, but China headwinds loom ahead of its Q1 earnings release.
Why Johnson & Johnson (JNJ) Is One of the Best Pharma Stocks to Invest in Now
02.04.2026 13:35
Johnson & Johnson (NYSE:JNJ) is one of the best pharma stocks to invest in now. Johnson & Johnson (NYSE:JNJ) announced on March 28 that randomized controlled trial (RCT) data presented at the American College of Cardiology (ACC) 2026, which was also published in the Journal of the American College of Cardiology, showed for the first time […]
JNJ Stock’s 60% Breakout: Why Wall Street is Torn
02.04.2026 12:01
Johnson & Johnson (JNJ) stock is up 62% over the last twelve months. For a healthcare giant typically filed under "boring and defensive," that's unusual. The move reflects a combination of a leaner post-spinoff business and fundamentals that have reframed J&J from a slow-moving conglomerate into a focused, high-quality compounder.
This Healthcare Stock Barely Flinches During Market Sell-Offs
02.04.2026 10:34
Shares of Johnson & Johnson have fallen by less than 2% over the past month, while the S&P 500 has fallen by more than 7%.
Is It Too Late To Consider Johnson & Johnson (JNJ) After Its 61% One-Year Surge?
02.04.2026 10:11
Investors may be wondering whether Johnson & Johnson is still reasonably priced after its strong run, or if the current share price already reflects most of the opportunity. The stock closed at US$244.12, with a 1.7% return over the last 7 days, a 1.8% decline over 30 days, and returns of 17.7% year to date and 61.5% over the last year. Recent coverage has focused on Johnson & Johnson's position as a large, diversified healthcare group and how its portfolio breadth can affect investor...
Royalty Pharma, Johnson & Johnson Strike $500M Autoimmune Drug Deal
02.04.2026 01:32
Johnson & Johnson (NYSE:JNJ) is included among the 13 Best Diversified Dividend Stocks to Buy Right Now. On March 30, Reuters reported that Royalty Pharma entered into a $500 million research and development agreement with Johnson & Johnson (NYSE:JNJ) to support an experimental antibody treatment for autoimmune diseases. Shares of JNJ moved up nearly 0.7% […]
Dow Jones Futures Rise, Oil Prices Fall Below $100; Trump To Speak To Nation On Iran War
01.04.2026 11:47
President Trump is eyeing an Iran war exit even if the Strait of Hormuz stays closed. Stocks soared, oil prices were mixed.
Johnson & Johnson (NYSE:JNJ) Stands Out as a Quality Dividend Stock for Reliable Income
01.04.2026 11:21
Johnson & Johnson (JNJ) exemplifies a quality dividend stock, offering a reliable and growing payout backed by strong profitability and solid financial health for long-term income.
Johnson & Johnson: The Return Of The Dividend King
31.03.2026 02:03
Consensus projects Johnson & Johnson's EPS CAGR of 8.9% (2026â2030), with forward P/E compressing from 20.8x to 14.8x. Read why JNJ stock is a Buy.
Johnson & Johnson’s JNJ-4804 Deal Adds Weight To Immunology Story
30.03.2026 17:06
Johnson & Johnson (NYSE:JNJ) has entered a $500m R&D co funding agreement with Royalty Pharma to advance JNJ-4804, a first in class co antibody therapy for autoimmune diseases. The collaboration focuses on a therapy that targets two immune pathways relevant to chronic autoimmune conditions. The agreement is positioned to support development of JNJ-4804 across multiple autoimmune indications. For investors watching NYSE:JNJ, this new R&D alliance comes as the stock trades at $240.45, with a...
This is Why Johnson & Johnson (JNJ) is a Great Dividend Stock
30.03.2026 15:45
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
Alumis' Drug 'Very Positive' for Treatment of Psoriasis, Systemic Lupus Erythematosus, Oppenheimer Says
30.03.2026 15:25
Alumis' (ALMS) recent phase 3 results for its psoriasis treatment envudeucitinib is "very positive"
5 Defensive Stocks to Buy Amid Market's Recent Bloodbath
30.03.2026 14:52
DUK, ETR, STZ, KO and JNJ emerge as defensive picks as market volatility spikes, offering stability through dividends, low beta, and steady growth strategies.
Where to Find Winning Stocks Amid the Iran War Breakdown
30.03.2026 14:17
Investors are rotating into dividend-paying energy stocks, legacy tech, and metals as volatility tied to the Iran war shakes markets.
Where to Finding Winning Stocks Amid the Iran War Breakdown
30.03.2026 14:17
Investors are rotating into dividend-paying energy stocks, legacy tech, and metals as volatility tied to the Iran war shakes markets.
Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones
30.03.2026 12:45
– Full enrollment of BLA-enabling trial complete, per prior guidance –– Topline NEXICART-2 Results Expected Q3 2026, followed by BLA submission and planned commercial launch –– Onboarded Chief Medical Officer, formerly of Merck and Johnson & Johnson for BLA submission – LOS ANGELES, CA, March 30, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that NEXICART-2 enrollment is com
Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases
30.03.2026 11:15
NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced a research and development (R&D) co-funding agreement with Johnson & Johnson for a total of $500 million in 2026 and 2027 to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. JNJ‑4804 is a novel co‑antibody therapy that blocks the complementary interleukin‑23 (IL‑23) and tumor necrosis factor (TNF) pathways, delivering synergistic effects on the pathogenesis of c
Non-Muscle Invasive Bladder Cancer (NMIBC) Market to Grow by $1 Billion During 2026-2030 - Johnson & Johnson, Janssen Research & Development, and Merck & Co. Lead the Competition
30.03.2026 09:25
Non-Muscle Invasive Bladder Cancer Market Non-Muscle Invasive Bladder Cancer Market Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Non-Muscle Invasive Bladder Cancer Market Report 2026" has been added to ResearchAndMarkets.com's offering. The non-muscle invasive bladder cancer (NMIBC) market size has experienced robust growth, increasing from $3.66 billion in 2025 to an anticipated $4.82 billion by 2030. This expansion is driven by factors such as a rise in early diagnosis, enhanced use of tran
Royalty Pharma Announces R&D Co-Funding Agreement With Johnson & Johnson For Total Of $500M In 2026 And 2027 To Advance Development Of JNJ-4804, Investigational Medicine For Autoimmune Diseases
30.03.2026 07:24
Royalty Pharma plc (NASDAQ:RPRX) today announced a research and development (R&D) co-funding agreement with Johnson & Johnson for a total of $500 million in 2026 and 2027 to advance the development of JNJ-4804,
NANOBIOTIX Announces Presentation of First Data from a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer
30.03.2026 06:30
Data presented by Johnson & Johnson at the 2026 European Lung Cancer Conference PARIS and CAMBRIDGE, Mass., March 30, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced the presentation of first data from the CONVERGE study, a Johnson & Johnson-sponsored randomized Phase 2 clinical